Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Acute coronary syndrome - rivaroxaban [ID532]: equality impact assessment - guidance review

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination  information

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document (PDF 420 KB)

Acute coronary syndrome - rivaroxaban [ID532]: committee papers information

Acute coronary syndrome - rivaroxaban [ID532]: consultation

Acute coronary syndrome - rivaroxaban [ID532]: consultation document

Acute coronary syndrome - rivaroxaban [ID532]: consultation document (PDF 414 KB)

Acute coronary syndrome - rivaroxaban [ID532]: supporting information information

Acute coronary syndrome - rivaroxaban: appendix B - final scope

Acute coronary syndrome - rivaroxaban: appendix C - final matrix

Acute Coronary Syndrome - rivaroxaban: NICEs response to consultee and commentator comments on provisional matrix (updated)

Acute coronary syndrome - rivaroxaban: equality impact assessment - scoping

Acute coronary syndrome - rivaroxaban: draft matrix for consultation (post-referral) - August 2012

Acute coronary syndrome - rivaroxaban: draft scope for consultation (post-referral) - August 2012

Acute coronary syndrome - rivaroxaban: appendix C - provisional matrix (pre-referral) - November 2011

Acute coronary syndrome - rivaroxaban: appendix B - draft scope for consultation (pre-referral) - November 2011